SB-424323

GlaxoSmithKline · Phase 2 active Small molecule

At a glance

Generic name	SB-424323
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) (PHASE2)
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SB-424323 CI brief — competitive landscape report
SB-424323 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI